These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 23725735)

  • 1. Two-year safety and efficacy of ranibizumab 0.5 mg in diabetic macular edema: interim analysis of the RESTORE extension study.
    Lang GE; Berta A; Eldem BM; Simader C; Sharp D; Holz FG; Sutter F; Gerstner O; Mitchell P;
    Ophthalmology; 2013 Oct; 120(10):2004-12. PubMed ID: 23725735
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Three-year outcomes of individualized ranibizumab treatment in patients with diabetic macular edema: the RESTORE extension study.
    Schmidt-Erfurth U; Lang GE; Holz FG; Schlingemann RO; Lanzetta P; Massin P; Gerstner O; Bouazza AS; Shen H; Osborne A; Mitchell P;
    Ophthalmology; 2014 May; 121(5):1045-53. PubMed ID: 24491642
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ranibizumab 0.5 mg for Diabetic Macular Edema with Bimonthly Monitoring after a Phase of Initial Treatment: 18-Month, Multicenter, Phase IIIB RELIGHT Study.
    Pearce I; Banerjee S; Burton BJ; Chakravarthy U; Downey L; Gale RP; Gibson J; Pagliarini S; Patel J; Sivaprasad S; Andrews C; Brittain C; Warburton J;
    Ophthalmology; 2015 Sep; 122(9):1811-9. PubMed ID: 26150052
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema.
    Mitchell P; Bandello F; Schmidt-Erfurth U; Lang GE; Massin P; Schlingemann RO; Sutter F; Simader C; Burian G; Gerstner O; Weichselberger A;
    Ophthalmology; 2011 Apr; 118(4):615-25. PubMed ID: 21459215
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The REVEAL Study: Ranibizumab Monotherapy or Combined with Laser versus Laser Monotherapy in Asian Patients with Diabetic Macular Edema.
    Ishibashi T; Li X; Koh A; Lai TY; Lee FL; Lee WK; Ma Z; Ohji M; Tan N; Cha SB; Shamsazar J; Yau CL;
    Ophthalmology; 2015 Jul; 122(7):1402-15. PubMed ID: 25983216
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The SECURE study: long-term safety of ranibizumab 0.5 mg in neovascular age-related macular degeneration.
    Silva R; Axer-Siegel R; Eldem B; Guymer R; Kirchhof B; Papp A; Seres A; Gekkieva M; Nieweg A; Pilz S;
    Ophthalmology; 2013 Jan; 120(1):130-9. PubMed ID: 23021093
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE.
    Brown DM; Nguyen QD; Marcus DM; Boyer DS; Patel S; Feiner L; Schlottmann PG; Rundle AC; Zhang J; Rubio RG; Adamis AP; Ehrlich JS; Hopkins JJ;
    Ophthalmology; 2013 Oct; 120(10):2013-22. PubMed ID: 23706949
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patient-reported visual function outcomes improve after ranibizumab treatment in patients with vision impairment due to diabetic macular edema: randomized clinical trial.
    Mitchell P; Bressler N; Tolley K; Gallagher M; Petrillo J; Ferreira A; Wood R; Bandello F;
    JAMA Ophthalmol; 2013 Oct; 131(10):1339-47. PubMed ID: 23974915
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-World Outcomes with Ranibizumab 0.5 mg in Patients with Visual Impairment due to Diabetic Macular Edema: 12-Month Results from the 36-Month BOREAL-DME Study.
    Massin P; Creuzot-Garcher C; Kodjikian L; Girmens JF; Delcourt C; Fajnkuchen F; Glacet-Bernard A; Guillausseau PJ; Ponthieux A; Blin P; Grelaud A
    Ophthalmic Res; 2019; 62(2):101-110. PubMed ID: 30928985
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ranibizumab for macular edema due to retinal vein occlusions: long-term follow-up in the HORIZON trial.
    Heier JS; Campochiaro PA; Yau L; Li Z; Saroj N; Rubio RG; Lai P
    Ophthalmology; 2012 Apr; 119(4):802-9. PubMed ID: 22301066
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration.
    Busbee BG; Ho AC; Brown DM; Heier JS; Suñer IJ; Li Z; Rubio RG; Lai P;
    Ophthalmology; 2013 May; 120(5):1046-56. PubMed ID: 23352196
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vision-related function after ranibizumab treatment for diabetic macular edema: results from RIDE and RISE.
    Bressler NM; Varma R; Suñer IJ; Dolan CM; Ward J; Ehrlich JS; Colman S; Turpcu A;
    Ophthalmology; 2014 Dec; 121(12):2461-72. PubMed ID: 25148789
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcomes with As-Needed Ranibizumab after Initial Monthly Therapy: Long-Term Outcomes of the Phase III RIDE and RISE Trials.
    Boyer DS; Nguyen QD; Brown DM; Basu K; Ehrlich JS;
    Ophthalmology; 2015 Dec; 122(12):2504-13.e1. PubMed ID: 26452713
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted Retinal Photocoagulation for Diabetic Macular Edema with Peripheral Retinal Nonperfusion: Three-Year Randomized DAVE Trial.
    Brown DM; Ou WC; Wong TP; Kim RY; Croft DE; Wykoff CC;
    Ophthalmology; 2018 May; 125(5):683-690. PubMed ID: 29336896
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A multicenter, 12-month randomized study comparing dexamethasone intravitreal implant with ranibizumab in patients with diabetic macular edema.
    Callanan DG; Loewenstein A; Patel SS; Massin P; Corcóstegui B; Li XY; Jiao J; Hashad Y; Whitcup SM
    Graefes Arch Clin Exp Ophthalmol; 2017 Mar; 255(3):463-473. PubMed ID: 27632215
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Three-year patient-reported visual function outcomes in diabetic macular edema managed with ranibizumab: the RESTORE extension study.
    Mitchell P; Massin P; Bressler S; Coon CD; Petrillo J; Ferreira A; Bressler NM
    Curr Med Res Opin; 2015 Nov; 31(11):1967-75. PubMed ID: 26327116
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vision-Related Quality of Life in Patients with Diabetic Macular Edema Treated with Intravitreal Aflibercept: The AQUA Study.
    Garweg JG; Stefanickova J; Hoyng C; Schmelter T; Niesen T; Sowade O; Sivaprasad S;
    Ophthalmol Retina; 2019 Jul; 3(7):567-575. PubMed ID: 31080168
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE.
    Nguyen QD; Brown DM; Marcus DM; Boyer DS; Patel S; Feiner L; Gibson A; Sy J; Rundle AC; Hopkins JJ; Rubio RG; Ehrlich JS;
    Ophthalmology; 2012 Apr; 119(4):789-801. PubMed ID: 22330964
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Individualized Stabilization Criteria-Driven Ranibizumab versus Laser in Branch Retinal Vein Occlusion: Six-Month Results of BRIGHTER.
    Tadayoni R; Waldstein SM; Boscia F; Gerding H; Pearce I; Priglinger S; Wenzel A; Barnes E; Gekkieva M; Pilz S; Monés J;
    Ophthalmology; 2016 Jun; 123(6):1332-44. PubMed ID: 27039022
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy/safety of ranibizumab monotherapy or with laser versus laser monotherapy in DME.
    Berger A; Sheidow T; Cruess AF; Arbour JD; Courseau AS; de Takacsy F
    Can J Ophthalmol; 2015 Jun; 50(3):209-16. PubMed ID: 26040221
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.